Stanford University
Showing 511-520 of 742 Results
-
Stanley Qi
Associate Professor of Bioengineering and, by courtesy, of Biomedical Data Science
BioStanley Qi (publishing as Lei S. Qi) is a pioneer in the field of genome engineering and the architect of the foundational technologies that transitioned CRISPR from a "cutting" tool into a universal platform for Programmable Biology. As the inventor of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), Qi established the first methods for the precise, reversible, and targeted regulation of the human genome without altering the DNA sequence.
The Qi Lab integrates scalable genomic perturbation with live-cell and super-resolution imaging and computation-guided design to redefine the boundaries of cellular control. Under Dr. Qi’s leadership, the group has fundamentally expanded the genome engineering toolbox, evolving CRISPR from a single editing tool into a multidimensional platform for the precise control of dynamic and spatial cell states. This work includes establishing foundational technologies and architectures for precise epigenetic editing, multiplexed regulation of the transcriptome, programmable 3D genome organization, and spatial control of RNA logistics. By pioneering real-time visualization of chromatin dynamics and RNA in living cells, the lab provides an unprecedented window into the fundamental "control principles of life."
This principle-driven technology lineage has moved into the clinic, with the lab's compact epigenetic editor currently in first-in-human clinical testing for FSHD muscular dystrophy (NCT06907875). This milestone represents a core mission of the lab: translating foundational engineering into next-generation therapeutics that act predictably as dynamic, complex systems.
Beyond single-cell control, the Qi Lab is building a framework for synthetic cell–cell communication, with a particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors.
By integrating computational design with experimental biology, Dr. Qi aims to identify the generalizable rules linking molecular programs to systems-level physiology. He is a Chan Zuckerberg Biohub Investigator and an Institute Scholar at the Sarafan ChEM-H, and is dedicated to shaping the technical and ethical frameworks that will define the future of human genome engineering. -
Xiaojie Qiu
Assistant Professor of Genetics and, by courtesy, of Computer Science
Current Research and Scholarly InterestsAt the Qiu Lab, our mission is to unravel and predict the intricacies of gene regulatory networks and cell-cell interactions pivotal in mammalian cell fate transitions over time and space, with a special emphasis on heart evolution, development, and disease. We are a dynamic and interdisciplinary team, harnessing the latest advancements in machine learning as well as single-cell and spatial genomics by integrating the predictive power of systems biology with the scalability of machine learning,
-
Stephen Quake
Lee Otterson Professor in the School of Engineering and Professor of Bioengineering, of Applied Physics and, by courtesy, of Physics
Current Research and Scholarly InterestsSingle molecule biophysics, precision force measurement, micro and nano fabrication with soft materials, integrated microfluidics and large scale biological automation.
-
Thomas Quertermous, MD
William G. Irwin Professor of Cardiovascular Medicine
Current Research and Scholarly InterestsUnderstanding genetic basis of cardiovascular function and disease.
-
Marlene Rabinovitch
Dwight and Vera Dunlevie Professor of Pediatric Cardiology
Current Research and Scholarly InterestsOur research program seeks to identify the cellular and molecular programs regulating vascular and lung development, through the use of cultured cells and tissues and mouse and rat models. We then determine how these programs are perturbed by genetic abnormalities or injurious processes associated with disease, focusing on pulmonary arterial hypertension (PAH), a fatal complication in children with heart defects, and a condition of unknown etiology primarily in young women.
-
Ralph Rabkin
Professor of Medicine, Emeritus
Current Research and Scholarly InterestsDr Rabkin is examining the mechanism of the acquired resistance to hormones that develops in kidney failure.In particular he is studying the impact of kidney failure on the action of growth hormone and the role of impaired signal transduction as a cause of growth hormone resistance. He is also engaged in the study of growth factors in diabetic kidney disease.
-
Thomas Raffin
The Colleen and Robert Haas Professor in Medicine and Biomedical Ethics, Emeritus
Current Research and Scholarly InterestsDr. Raffin is a clinician, teacher and investigator. He retired as Chief of the Division of Pulmonary and Critical Care Medicine in 2004. His key areas of academic interest include the biology and management of acute lung injury; basic biology of human lung and white cells; and, key issues in biomedical ethics including withholding and withdrawing life support, health care delivery, genomics, genetic screening, and neuroethics.
